CDER’s latest proposal to withdraw the accelerated approval of Makena (HPC) was dependent upon a large randomized demo that failed to verify the benefit of this drug to newborns or lower the potential risk of PTB. In earning the decision to propose Makena’s withdrawal, CDER also reviewed results from prior scientific studies of progestins (HP